SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status
暂无分享,去创建一个
J. W. Askew | R. Kortum | K. Fisher | Brianna Daley | R. Svoboda | Nancy E. Sealover | Dianna H. Huisman | Heidi Vieira | Deepan Chatterjee | R. Lewis | Chaitra Rao | Katherine Cox | Jacob M. Hughes | Zaria M. Beckley | D. Chatterjee | Heidi M. Vieira
[1] R. Kortum,et al. In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies , 2023, bioRxiv.
[2] M. Ladanyi,et al. MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression , 2022, npj Precision Oncology.
[3] R. Kortum,et al. Heterogeneity in RAS mutations: One size does not fit all , 2022, Science Signaling.
[4] E. Petricoin,et al. Functional and biological heterogeneity of KRASQ61 mutations , 2022, Science Signaling.
[5] J. Mazières,et al. Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer , 2022, Cancers.
[6] T. Pons,et al. KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors , 2022, Molecular oncology.
[7] G. Kroemer,et al. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges , 2021, Molecular cancer.
[8] Fang Wu,et al. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.
[9] Anna M. Schmoker,et al. Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation , 2021, Proceedings of the National Academy of Sciences.
[10] M. Tsao,et al. Mechanism of drug tolerant persister cancer cells: The landscape and clinical implication for therapy. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] B. Garcia,et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting , 2021, Nature Communications.
[12] D. Carbone,et al. Targeting KRAS in non-small cell lung cancer: recent progress and new approaches. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] A. Hata,et al. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer , 2021, Cancers.
[14] R. Kortum,et al. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS. , 2021, Journal of medicinal chemistry.
[15] N. Kraut,et al. Targeting Son of Sevenless 1: The pacemaker of KRAS. , 2021, Current opinion in chemical biology.
[16] P. Ettmayer,et al. One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS. , 2021, Journal of medicinal chemistry.
[17] Robert E. Lewis,et al. KSR1- and ERK-dependent translational regulation of the epithelial-to-mesenchymal transition , 2021, bioRxiv.
[18] Zhentao Yang,et al. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity. , 2020, Cancer discovery.
[19] S. Y. Kim,et al. Update 2020: Management of Non-Small Cell Lung Cancer , 2020, Lung.
[20] William M. Marsiglia,et al. Structural basis for the action of the drug trametinib at KSR-bound MEK , 2020, Nature.
[21] Mary E. Duffy,et al. Structural basis for the action of the drug trametinib at KSR-bound MEK , 2020, Nature.
[22] R. Kortum,et al. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer , 2020, eLife.
[23] P. Ettmayer,et al. BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. , 2020, Cancer discovery.
[24] M. McMahon,et al. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. , 2020, Cell reports.
[25] A. Adjei,et al. KRAS: From undruggable to a druggable Cancer Target. , 2020, Cancer treatment reviews.
[26] Laura E. Herring,et al. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers , 2020, Cell reports.
[27] G. Tortora,et al. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives , 2020, Cancers.
[28] J. Hartley,et al. The Frequency of Ras Mutations in Cancer , 2020, Cancer Research.
[29] A. Hata,et al. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. , 2020, Pharmacology & therapeutics.
[30] Davide Risso,et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition , 2020, Nature.
[31] Henry W. Long,et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. , 2020, Cancer cell.
[32] Hiromasa Yamamoto,et al. YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers , 2019, Cancer Science.
[33] D. Esposito,et al. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling. , 2019, Molecular cell.
[34] F. Fece de la Cruz,et al. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition , 2019, Clinical Cancer Research.
[35] J. Fernandez-Banet,et al. The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.
[36] R. Doebele. Acquired Resistance Is Oncogene and Drug Agnostic. , 2019, Cancer cell.
[37] Joshua M. Dempster,et al. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. , 2019, Cell reports.
[38] N. Haginoya,et al. DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model , 2019, Oncotarget.
[39] J. Ahn,et al. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer , 2019, Investigational New Drugs.
[40] M. Ebert,et al. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer , 2019, Nature Communications.
[41] R. Kortum,et al. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells , 2019, Small GTPases.
[42] Donghwa Kim,et al. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells , 2019, Cell Death & Disease.
[43] R. Rosell,et al. Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer. , 2019, Clinical lung cancer.
[44] H. Briem,et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction , 2019, Proceedings of the National Academy of Sciences.
[45] Yue Yu,et al. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency , 2019, Clinical Cancer Research.
[46] S. Yano,et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells , 2019, Nature Communications.
[47] G. Vassalli. Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells , 2019, Stem cells international.
[48] R. Sachidanandam,et al. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors , 2019, Cell reports.
[49] J. Kinney,et al. A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence. , 2018, Cancer cell.
[50] J. Soh,et al. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells , 2018, Molecular Cancer Research.
[51] Dong-Wan Kim,et al. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib , 2018, Cancer research and treatment : official journal of Korean Cancer Association.
[52] D. Morrison,et al. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation , 2018, Science Signaling.
[53] Channing J Der,et al. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.
[54] B. Neel,et al. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. , 2018, Cancer discovery.
[55] Krister Wennerberg,et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells , 2018, Science Translational Medicine.
[56] G. Kiss,et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers , 2018, Nature Cell Biology.
[57] T. Salame,et al. A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways , 2018, Clinical Cancer Research.
[58] R. Bernards,et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo , 2018, Nature Medicine.
[59] J. Soh,et al. Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations , 2018, Cancer science.
[60] Ken Chen,et al. Systematic Functional Annotation of Somatic Mutations in Cancer. , 2018, Cancer cell.
[61] P. Zarrinkar,et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.
[62] T. Salame,et al. An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors , 2017, EMBO molecular medicine.
[63] M. Tiseo,et al. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines , 2017, Journal of experimental & clinical cancer research : CR.
[64] T. Bivona,et al. Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.
[65] H. Clevers,et al. Cancer stem cells revisited , 2017, Nature Medicine.
[66] K. O'Byrne,et al. Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC , 2017, Oncotarget.
[67] Lorin Crawford,et al. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. , 2017, Cell reports.
[68] A. Jimeno,et al. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. , 2017, Cancer research.
[69] M. Varella‐Garcia,et al. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling , 2017, Molecular Cancer Therapeutics.
[70] R. Weinberg,et al. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.
[71] Ying Tang,et al. Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency , 2017, Science Translational Medicine.
[72] S. Haan,et al. Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies , 2017, Molecular Cancer.
[73] L. Qu,et al. At the crossroads of cancer stem cells and targeted therapy resistance. , 2017, Cancer letters.
[74] R. Salgia,et al. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. , 2016, Cancer letters.
[75] A. Dar,et al. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling , 2016, Nature.
[76] J. Grilley-Olson,et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors , 2016, Investigational New Drugs.
[77] Peter K. Sorger,et al. Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway , 2016, Science Signaling.
[78] Robert E. Lewis,et al. KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors , 2016, Molecular and Cellular Biology.
[79] C. Rudin,et al. A combinatorial strategy for treating KRAS mutant lung cancer , 2016, Nature.
[80] Jae Cheol Lee,et al. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer , 2016, Oncotarget.
[81] E. Petricoin,et al. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. , 2016, Cancer cell.
[82] M. Nowak,et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers , 2015, Nature Communications.
[83] Robert E. Lewis,et al. AMPK Promotes Aberrant PGC1β Expression To Support Human Colon Tumor Cell Survival , 2015, Molecular and Cellular Biology.
[84] S. Asthana,et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer , 2015, Nature Medicine.
[85] Sourav Bandyopadhyay,et al. Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions. , 2015, Cancer research.
[86] W. Pao,et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. , 2015, Cancer research.
[87] John C. Hunter,et al. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.
[88] P. Jänne,et al. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. , 2015, Cancer discovery.
[89] Kevin Struhl,et al. Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation , 2015, Proceedings of the National Academy of Sciences.
[90] Frank McCormick,et al. KRAS as a Therapeutic Target , 2015, Clinical Cancer Research.
[91] J. Meller,et al. Combined Rational Design and a High Throughput Screening Platform for Identifying Chemical Inhibitors of a Ras-activating Enzyme* , 2015, The Journal of Biological Chemistry.
[92] Parantu K. Shah,et al. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. , 2015, Cancer research.
[93] Emmanuel C. Alozie,et al. Promises and Challenges , 2015 .
[94] T. Bekaii-Saab,et al. Selumetinib for the treatment of cancer , 2015, Expert opinion on investigational drugs.
[95] Yi Zheng,et al. Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. , 2014, Chemistry & biology.
[96] M. Cristofanilli,et al. Cancer stem cells: implications for cancer therapy. , 2014, Oncology.
[97] P. Poulikakos,et al. Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.
[98] J. Rodríguez-Fernández,et al. A Novel MEK-ERK-AMPK Signaling Axis Controls Chemokine Receptor CCR7-dependent Survival in Human Mature Dendritic Cells* , 2014, The Journal of Biological Chemistry.
[99] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[100] D. Carbone,et al. EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. , 2014, Cancer research.
[101] R. Bernards,et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. , 2014, Cell reports.
[102] John D. Minna,et al. Essential Role of Aldehyde Dehydrogenase 1A3 for the Maintenance of Non–Small Cell Lung Cancer Stem Cells Is Associated with the STAT3 Pathway , 2014, Clinical Cancer Research.
[103] D. Raha,et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. , 2014, Cancer research.
[104] Andreas Schlicker,et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.
[105] P. Bunn,et al. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer , 2013, PloS one.
[106] Alexey I. Nesvizhskii,et al. Reconstructing targetable pathways in lung cancer by integrating diverse omics data , 2013, Nature Communications.
[107] P. L. McCormack,et al. Trametinib: First Global Approval , 2013, Drugs.
[108] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[109] Mitsuhiko Ikura,et al. NMR-based functional profiling of RASopathies and oncogenic RAS mutations , 2013, Proceedings of the National Academy of Sciences.
[110] Chin-Lee Wu,et al. Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[111] Carlotta Costa,et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. , 2012, Cancer research.
[112] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[113] Min Yu,et al. TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers , 2012, Cell.
[114] Robert E. Lewis,et al. Kinase Suppressor of Ras 1 (KSR1) Regulates PGC1α and Estrogen-Related Receptor α To Promote Oncogenic Ras-Dependent Anchorage-Independent Growth , 2011, Molecular and Cellular Biology.
[115] Marian Kelley,et al. One size does not fit all. , 2011, Bioanalysis.
[116] Laura A. Sullivan,et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. , 2010, Cancer research.
[117] Robert E. Lewis,et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. , 2009, Cell metabolism.
[118] William Pao,et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer , 2009, Proceedings of the National Academy of Sciences.
[119] G. Smyth,et al. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.
[120] Deborah K. Morrison,et al. Signaling dynamics of the KSR1 scaffold complex , 2009, Proceedings of the National Academy of Sciences.
[121] Patricia Greninger,et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.
[122] Sridhar Ramaswamy,et al. Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.
[123] Feng Jiang,et al. Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer , 2009, Molecular Cancer Research.
[124] Jun Wang,et al. Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells , 2006, Cancer biology & therapy.
[125] Robert E. Lewis,et al. The Molecular Scaffold Kinase Suppressor of Ras 1 Is a Modifier of RasV12-Induced and Replicative Senescence , 2006, Molecular and Cellular Biology.
[126] Hiroshi Sakaue,et al. The Molecular Scaffold Kinase Suppressor of Ras 1 (KSR1) Regulates Adipogenesis , 2005, Molecular and Cellular Biology.
[127] Robert E. Lewis,et al. The Molecular Scaffold KSR1 Regulates the Proliferative and Oncogenic Potential of Cells , 2004, Molecular and Cellular Biology.
[128] R. Kolesnick,et al. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. , 2003, Cancer research.
[129] Kenneth M. Murphy,et al. Kinase Suppressor of Ras (KSR) Is a Scaffold Which Facilitates Mitogen-Activated Protein Kinase Activation In Vivo , 2002, Molecular and Cellular Biology.
[130] R. Klemke,et al. Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility* , 1999, The Journal of Biological Chemistry.
[131] G. Rubin,et al. Identification of Constitutive and Ras-Inducible Phosphorylation Sites of KSR: Implications for 14-3-3 Binding, Mitogen-Activated Protein Kinase Binding, and KSR Overexpression , 1999, Molecular and Cellular Biology.
[132] A. Wolfman,et al. Oncogenic Ha-Ras-dependent Mitogen-activated Protein Kinase Activity Requires Signaling Through the Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.
[133] E. Goldsmith,et al. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation , 1998, Current Biology.
[134] J. Hancock,et al. Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase* , 1998, The Journal of Biological Chemistry.
[135] R. Hillig,et al. Targeting RAS oncogenesis with SOS1 inhibitors. , 2022, Advances in cancer research.
[136] C. Der,et al. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. , 2022, Advances in cancer research.
[137] E. Ortiz-Sánchez,et al. ALDH as a Stem Cell marker in solid tumors. , 2018, Current stem cell research & therapy.
[138] C. Dai,et al. Visualization of RAS/MAPK Signaling In Situ by the Proximity Ligation Assay (PLA). , 2017, Methods in molecular biology.
[139] J. Shih,et al. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. , 2013, Cancer letters.